Agenus

AGEN · NASDAQ

$6.42+$0.24 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.18

About AGEN

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Employees: 81
Headquarters: Lexington, Massachusetts
Listed: Feb 4, 2000
Sector: Health Care
Industry: Biotechnology
Website: agenusbio.com

Leadership

Agenus executives
Name	Title	Since	Age
Garo Armen	—	1994	72
Christine Klaskin	—	—	59
Richard Goldberg	—	—	—
Steven O'Day	—	—	64
Timothy Wright	—	—	67
Jennifer Buell	—	2018	51
Brian Corvese	—	—	67
Thomas Harrison	—	—	77
Susan Hirsch	—	—	72

Revenue by product and region

Fiscal year ended Dec 31, 2025: $114.20M total revenue

By product

Non Cash Revenue Related To Sale Of Future Royalties [Member]$108.59M95.1%
Pre Commercial Product Revenue [Member]$4.24M3.7%
Service Revenue [Member]$1.04M0.9%

By region

United States [Member]$113.16M99.1%
Rest of World [Member]$1.04M0.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Agenus suppliers and customers
Company	Relationship	Country	Correlation
Targovax TRVX.OL	Supplier and customer	NO	0.92
UroGen Pharma URGN	Supplier and customer	US	0.90
Betta Pharmaceuticals A	Supplier and customer	CN	0.80
Ginkgo Bioworks A DNA	Supplier and customer	US	0.72
Gilead Sciences GILD	Supplier and customer	US	0.57
Viatris VTRS	Supplier and customer	US	0.57
Incyte INCY	Supplier and customer	US	0.08
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.41
Merck & Co MRK	Supplier and customer	US	-0.54
GlaxoSmithKline GSK.L	Supplier and customer	GB	-0.87

Similar companies

Companies in the same industry as Agenus

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.